title: Good response of malignant pleural effusion from carcinoma of unknown primary site to the anti-tuberculosis therapy: a case report.
abstract: Malignant pleural effusion in patients with cancers or malignant pleural mesothelioma may often appear at the late stage of disease and significantly affect the patients' life quality and survival. However, there is still no very effective treatment to control malignant pleural effusion. Here we report that malignant pleural effusion in one patient was completely relieved for 15 months by the anti-tuberculosis therapy.
  
  
  METHODS
  A 54-year-old female patient complained of cough, dyspnea, chest pain, night sweat and light fever in the afternoon. Computed tomography (CT) of the chest revealed bilateral pleural effusion. But no tumor was found in the lung, pleura and in other sites. Blood test revealed serum carcinoembryonic antigen (CEA) level at 300 ng/mL. One week after we tried anti-tuberculosis combined therapy with isoniazid, pyrazinamide, rifapentine and ethambutol. The pleural effusion in patient was eliminated, along with decreasing CEA. But the CEA increased gradually again when the anti-tuberculosis treatment was forced to discontinuation. Sixteen months after anti-tuberculosis treatment, the symptoms of cough and breathing difficulty relapsed. Chest CT revealed left pleural effusion, pleural thickness and pericardium nodules. Thoracoscopy and biopsy were conducted. The pleural nodules specimen was pathologically diagnosed as squamous cell carcinoma.
  
  
  CONCLUSIONS
  We reported a rare case of successfully treating malignant pleural effusion caused by squamous cell carcinoma of unknown primary site with the anti-tuberculosis combined. This report provides useful evidences for that the anti-tubercular agents may have potential anticancer activity in some carcinomas.
authors: Department of respiratory medicine, Xiangya Hospital affiliated to Central South University, Changsha City, Hunan, 410008, P.R. China. guqihua@yahoo.com.cn
authors: Qihua
authors: Q
authors: Gu
authors: Chengping
authors: C
authors: Hu
authors: Jingjing
authors: J
authors: Qu
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use*; D002272:Carcinoembryonic Antigen / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000188:drug therapy* / Q000556:secondary*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009382:Neoplasms, Unknown Primary / Q000097:blood / Q000188:drug therapy*; D016066:Pleural Effusion, Malignant / Q000097:blood / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D002272:Carcinoembryonic Antigen
keywords: Malignant pleural effusion; anti-tuberculosis therapy; carcinoembryonic antigen (CEA)
references: Respiration. 2012;83(5):367-76
references: 22584211
references: Thorac Cardiovasc Surg. 2010 Sep;58(6):350-3
references: 20824588
references: Ann Thorac Cardiovasc Surg. 2013;19(5):351-7
references: 23237927
references: Anticancer Res. 2012 Nov;32(11):5131-4
references: 23155293
references: Eur J Cancer. 2003 Sep;39(14):1990-2005
references: 12957453
references: Med Clin North Am. 2011 Nov;95(6):1055-70
references: 22032427
references: Respiration. 2012;83(4):277-92
references: 22456231
references: Thorac Surg Clin. 2013 Feb;23(1):25-42, v-vi
references: 23206715
references: Anticancer Res. 1991 Jan-Feb;11(1):281-7
references: 2018362
references: Acta Pol Pharm. 2012 Sep-Oct;69(5):843-50
references: 23061279
references: J Thorac Oncol. 2011 Mar;6(3):592-7
references: 21258256